Patents Assigned to Pozen Inc.
-
Publication number: 20100330179Abstract: The present disclosure is directed to a method for treating a disease or disorder in a patient at risk of developing an NSAID-associated ulcer by administering to said patient in need thereof a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof to said at risk patient and thereby decreasing the patient's risk of developing an ulcer.Type: ApplicationFiled: June 24, 2010Publication date: December 30, 2010Applicants: ASTRAZENECA AB, POZEN INC.Inventors: Brian Ault, Clara Hwang, Everardus Orlemans, John R. Plachetka, Mark Sostek
-
Publication number: 20100062064Abstract: The present disclosure is directed to a method for delivering a pharmaceutical composition to a patient in need thereof, comprising: administering to said patient a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereofType: ApplicationFiled: September 3, 2009Publication date: March 11, 2010Applicants: ASTRAZENECA UK LTD., POZEN INC.Inventors: Brian Ault, Mark Sostek, Everardus Orlemans, John R. Plachetka
-
Publication number: 20080175897Abstract: The present invention is directed to dosage forms that can be used in therapeutic methods involving the oral co-administration of a combination of at least two drugs, one of which impairs gastrointestinal absorption and one of which does not. The dosage forms are designed so that the drug impairing absorption is not released into the gastrointestinal tract of a patient until after the drugs that do not impair absorption have been released and substantially absorbed. The invention may be used in treatment of migraine using a combination of triptans and NSAIDs or in the treatment of pain using a combination of NSAIDs and opioid analgesics.Type: ApplicationFiled: December 6, 2007Publication date: July 24, 2008Applicant: POZEN INC.Inventors: John Plachetka, Donna Gilbert
-
Patent number: 7332183Abstract: The present invention is directed to multilayer pharmaceutical tablets in which an NSAID and a triptan are present in separate and distinct layers. The layers are in a side-by-side configuration, which allows the dissolution of triptan and NSAID to occur independently and immediately.Type: GrantFiled: December 22, 2003Date of Patent: February 19, 2008Assignee: Pozen Inc.Inventors: John R. Plachetka, Venkata Markandeya Kothapalli, Donna L. Gilbert
-
Publication number: 20070207200Abstract: The present invention is directed to dosage forms that can be used in therapeutic methods involving the oral co-administration of a combination of at least two drugs, one of which impairs gastrointestinal absorption and one of which does not. The dosage forms are designed so that the drug impairing absorption is not released into the gastrointestinal tract of a patient until after the drugs that do not impair absorption have been released and substantially absorbed. The invention may be used in treatment of migraine using a combination of triptans and NSAIDs or in the treatment of pain using a combination of NSAIDs and opioid analgesics.Type: ApplicationFiled: March 2, 2007Publication date: September 6, 2007Applicant: POZEN INC.Inventors: John Plachetka, Donna Gilbert
-
Publication number: 20060178348Abstract: The present invention is directed to compositions containing an anti-inflammatory compound that acts by blocking protein extravasation together with an NSAID. These compositions may be used to treat inflammation and pain, especially headache pain. The invention also includes methods in which these drugs are separately administered to a patient.Type: ApplicationFiled: January 13, 2006Publication date: August 10, 2006Applicant: POZEN Inc.Inventor: John Plachetka
-
Publication number: 20060178349Abstract: The present invention is directed to compositions containing a 5-HT1F-specific agonist that acts by blocking protein extravasation together with an NSAID. These compositions may be used to treat migraine and headache pain. The invention also includes methods in which these drugs are separately administered to a patient.Type: ApplicationFiled: January 17, 2006Publication date: August 10, 2006Applicant: POZEN Inc.Inventor: John Plachetka
-
Publication number: 20060165797Abstract: The present invention is directed to drug dosage forms that can be used to treat diseases characterized by abnormal gastric acid secretion. The dosage forms have a core containing a proton pump inhibitor surrounded by an enteric coating or multiple particles containing proton pump inhibitor, each particle being surrounded by an enteric coating. The enteric coating delays the release of drug until the surrounding pH has risen. The tablets also include an outer coating that contains either a proton pump inhibitor or an H2 blocker. The outer coating is designed to rapidly dissolve in a patient's stomach.Type: ApplicationFiled: January 10, 2006Publication date: July 27, 2006Applicant: POZEN Inc.Inventor: John Plachetka
-
Patent number: 7060694Abstract: The present invention is directed to improved formulations for dihydroergotamine in which the drug is present at a concentration of at least 2.9 mM. The invention encompasses methods for using these formulations in treating patients for migraine headaches and the packaging of formulation into prefilled syringes for self-administration by patients.Type: GrantFiled: October 29, 2002Date of Patent: June 13, 2006Assignee: Pozen Inc.Inventors: John R. Plachetka, Donna Gilbert
-
Patent number: 7030162Abstract: The invention is directed to pharmaceutical compositions useful in the treatment of migraine. The compositions contain metoclopramide and one or more NSAIDs in unit dosage form. By selecting NSAIDs that are non-acidic or segregating the metoclopramide and NSAID, the storage life of the compositions has been increased. Also disclosed are coordinated dosage forms for the sequential release of drugs. The invention encompasses methods of treating migraine using any of these dosage forms.Type: GrantFiled: September 26, 2002Date of Patent: April 18, 2006Assignee: POZEN Inc.Inventors: John R. Plachetka, Zakauddin T. Chowhan
-
Publication number: 20050249811Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.Type: ApplicationFiled: May 16, 2005Publication date: November 10, 2005Applicant: POZEN Inc.Inventor: John Plachetka
-
Patent number: 6926907Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.Type: GrantFiled: May 31, 2002Date of Patent: August 9, 2005Assignee: Pozen Inc.Inventor: John R. Plachetka
-
Publication number: 20040180089Abstract: The present invention is directed to multilayer pharmaceutical tablets in which an NSAID and a triptan are present in separate and distinct layers. The layers are in a side-by-side configuration, which allows the dissolution of triptan and NSAID to occur independently and immediately.Type: ApplicationFiled: December 22, 2003Publication date: September 16, 2004Applicant: POZEN Inc.Inventors: John R. Plachetka, Venkata Markandeya Kothapalli, Donna L. Gilbert
-
Publication number: 20030232876Abstract: The invention is directed to methods and compositions that can be used in the treatment of headaches. In particular, methods and compositions are described involving the combination of a long-acting NSAID and a 5-HT1B/1D agonist.Type: ApplicationFiled: April 16, 2003Publication date: December 18, 2003Applicant: POZEN, Inc.Inventor: John R. Plachetka
-
Patent number: 6586458Abstract: The invention is directed to methods and compositions that can be used in the treatment of headaches. In particular, methods and compositions are described involving the combination of a long-acting NSAID and a 5-HT agonist. Included among the long-acting NSAIDs are cyclo-oxygenase-2 inhibitors.Type: GrantFiled: April 27, 2000Date of Patent: July 1, 2003Assignee: Pozen Inc.Inventor: John R. Plachetka
-
Publication number: 20030114476Abstract: The present invention is directed to improved formulations for dihydroergotamine in which the drug is present at a concentration of at least 2.9 mM. The invention encompasses methods for using these formulations in treating patients for migraine headaches and the packaging of formulation into prefilled syringes for self-administration by patients.Type: ApplicationFiled: October 29, 2002Publication date: June 19, 2003Applicant: POZEN Inc.Inventors: John R. Plachetka, Donna Gilbert
-
Publication number: 20030069255Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.Type: ApplicationFiled: May 31, 2002Publication date: April 10, 2003Applicant: POZEN Inc.Inventor: John R. Plachetka
-
Publication number: 20030040537Abstract: The invention is directed to pharmaceutical compositions useful in the treatment of migraine. The compositions contain metoclopramide and one or more NSAIDs in unit dosage form. By selecting NSAIDs that are non-acidic or segregating the metoclopramide and NSAID, the storage life of the compositions has been increased. Also disclosed are coordinated dosage forms for the sequential release of drugs. The invention encompasses methods of treating migraine using any of these dosage forms.Type: ApplicationFiled: September 26, 2002Publication date: February 27, 2003Applicant: POZEN Inc.Inventors: John R. Plachetka, Zakauddin T. Chowhan
-
Patent number: 6495535Abstract: The present invention is directed to improved formulations for dihydroergotamine in which the drug is present at a concentration of at least 2.9 mM. The invention encompasses methods for using these formulations in treating patients for migraine headaches and the packaging of formulation into prefilled syringes for self-administration by patients.Type: GrantFiled: March 15, 2000Date of Patent: December 17, 2002Assignee: Pozen Inc.Inventors: John R. Plachetka, Donna Gilbert
-
Patent number: 6479551Abstract: The invention is directed to pharmaceutical compositions useful in the treatment of migraine. The compositions contain metoclopramide and one or more NSAIDs in unit dosage form. By selecting NSAIDs that are non-acidic or segregating the metoclopramide and NSAID, the storage life of the compositions has been increased. Also disclosed are coordinated dosage forms for the sequential release of drugs. The invention encompasses methods of treating migraine using any of these dosage forms.Type: GrantFiled: March 3, 2000Date of Patent: November 12, 2002Assignee: Pozen Inc.Inventors: John R. Plachetka, Zakauddin T. Chowhan